

# Restoration of functional full-length dystrophin after intramuscular transplantation of Foamy Virus-transduced myoblasts

Jinhong Meng<sup>1,2</sup>; Nathan Paul Sweeney<sup>3</sup>; Bruno Doreste<sup>1,2</sup>; Francesco Muntoni<sup>1,2</sup>;  
Myra McClure<sup>3</sup> and Jennifer Morgan<sup>1,2\*</sup>

## Affiliations:

**1. Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH**

**2. National Institute for Health Research, Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London, London WC1N 1EH, United Kingdom**

**3. Jefferiss Research Trust laboratories, Imperial College London, London, United Kingdom**

**\*Correspondence should be addressed to:**

**J.E.M. (jennifer.morgan@ucl.ac.uk)**

**Dubowitz Neuromuscular Centre, Molecular Neurosciences Section, Developmental Neuroscience Programme, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH**

**Email: jennifer.morgan@ucl.ac.uk**

**Telephone: 00442079052874**

**Fax: 00442079052832**

**Short title: Restoration of full-length dystrophin *in vivo***

## Abstract

Stem cell therapy is a promising strategy to treat muscle diseases such as Duchenne muscular dystrophy (DMD). To avoid immune-rejection of donor cells or donor-derived muscle, autologous cells which have been genetically modified to express dystrophin are preferable to cells derived from healthy donors. Restoration of full-length dystrophin using viral vectors is extremely challenging, due to the limited packaging capacity of the vectors, but we have recently shown that either a foamy viral or lentiviral vector is able to package full-length dystrophin open-reading-frame and transduce myoblasts derived from a DMD patient. Differentiated myotubes derived from these transduced cells produced full-length dystrophin. Here, we transplanted the foamy viral-dystrophin corrected DMD myoblasts intramuscularly into *mdx* nude mice, and showed that the transduced cells contributed to muscle regeneration, expressing full-length dystrophin in nearly all the muscle fibres of donor origin. Further, we showed that the restored full-length dystrophin recruited members of the dystrophin-associated protein complex and nNOS within donor-derived muscle fibres, evidence that the restored dystrophin protein is functional. Dystrophin-expressing donor-derived muscle fibres expressed lower levels of utrophin than host muscle fibres, providing additional evidence of functional improvement of donor-derived myofibres. This is the first *in vivo* evidence that foamy virus vector transduced DMD myoblasts can contribute to muscle regeneration and mediate functional dystrophin restoration following their intra-muscular transplantation, representing a promising therapeutic strategy for individual small muscles in DMD.

## Introduction

Duchenne muscular dystrophy (DMD) is an X-linked disorder affecting 1:5000 boys worldwide (1). The disease is caused by lack of dystrophin, leading to muscle fibre necrosis and progressive weakness. In mouse models of DMD, transplanted normal muscle stem cells contribute to muscle regeneration and reconstitute the muscle stem cell pool (2;3), evidence that stem cell transplantation might be a promising therapeutic strategy to treat DMD. To avoid immune-rejection, autologous, genetically-modified stem cells (4) would be preferable to allogeneic stem cells. To correct the dystrophin mutation in patient cells, one could use clustered, regularly interspaced, short palindromic repeats -associated Cas9 (CRISPR-Cas9)- mediated gene editing (5-7), but this method is highly mutation-dependent. Different gene editing strategies need to be designed and tested for patients with different dystrophin mutations. This is time consuming and editing efficiency is not always guaranteed. In contrast, viral vectors, in particular integrating retroviral or lentiviral vectors, which correct the autologous stem cells by introducing extra copies of the dystrophin coding sequence into the genome, are applicable to all patients, regardless of mutation. For therapeutic purposes, full-length dystrophin (FL-dys) is preferable to mini-dystrophin, as only the former contains all of the functional motifs and should fully restore the muscle fibre function. However, the delivery of FL-dys to DMD stem cells using viral vectors has been challenging due to the large size of the FL-dys coding sequence (around 11Kb) and the relatively limited packaging capacity of the therapeutic virus vectors.

Foamy virus (FV) is one of the largest retroviruses, having a packaging capacity of 12-13 Kb, which could accommodate the FL-dys open reading frame (ORF, 11kb). FV is not endemic in humans (8). High throughput (9) or large-scale (10) integration site analysis on FV-transduced human fibroblasts or CD34+ hematopoietic cells showed that FV seldom integrated within genes, changed gene expression or integrated into active oncogenes, suggesting a unique highly desirable safety profile over that of the lentivirus (LV) and gamma-retrovirus (9;10). FV-transduced hematopoietic stem cells have been used in pre-clinical animal models to treat dogs with severe erythroid disease (11). The fact that FV can infect both dividing and quiescent cells, and is able to persist in quiescent cells (8), makes

it an attractive vector for transducing muscle stem cells, which, following transplantation, give rise to satellite cells (most of which are quiescent in normal adult muscle) *in vivo*.

We have recently shown that the 11Kb insert of FL-dys could be packaged in either a LV (12) or a FV vector (13) and both effectively transduced DMD myoblasts, suggesting that such a cell-mediated gene therapy might be applicable to treat DMD. But the efficiency of this approach, and the functionality of the restored full-length dystrophin, need to be tested in animal models before moving to clinical application. To efficiently deliver the FL-dys into DMD patient muscle cells, a vector leading to a high level of transgene expression would be ideal. In our recent LV work, the FL-dys we used was the native form of the dystrophin coding sequence (12); while in the FV study (13), we used codon-optimized full length dystrophin (coFLDys), which may result in higher protein expression than the native form of dystrophin (14;15). The LV-dystrophin vectors contained a GFP cassette, which facilitated the enrichment of the transduced cells via FACS sorting, but also limit its clinical application due to potential toxicity caused by the expression of GFP (16). On the contrary, the FV-dystrophin vector is devoid of such a selection cassette, making it more clinical applicable.

Here, we transplanted DMD myoblasts which had been transduced with FV coding for coFLDys into cryodamaged muscles of immunodeficient, dystrophin-deficient *mdx* mice, and determined their transplantation efficiency, restoration of full-length dystrophin and the functionality of the restored dystrophin within muscle fibres of donor origin. Our study provides evidence that restoration of full-length dystrophin in skeletal muscle mediated by virally-transduced DMD myoblasts is feasible and might be a promising therapeutic strategy for DMD.

## Materials and Methods

### 1. Ethics

The work was performed under the NHS National Research Ethics: Setting up of a rare diseases biological samples bank (biobank) for research to facilitate pharmacological, gene and cell therapy trials in neuromuscular disorders (REC reference number: 06/Q0406/33); and the use of cells as a model system to study pathogenesis and therapeutic strategies for Neuromuscular Disorders (REC reference 13/LO/1826).

Mice were bred and experimental procedures were carried out in the Biological Services Unit, University College London Great Ormond Street Institute of Child Health, in accordance with the Animals (Scientific Procedures) Act 1986.

Experiments were performed under Home Office licence numbers 70/7086 and 8389. Experiments were approved by the local University College London ethical committee prior to the licence being granted.

Mice were fed Envigo diet 2918. Envigo diet 2919 was used for damp diet, given to the mice after surgery. Both diets were irradiated. Mice were kept in individually-ventilated Techniplast Green Line cages, on 12 hour light/12 hour dark cycle.

### 2. Foamy virus vector production

FV-coFLDys is a self-inactivating foamy virus vector that encode the full-length dystrophin protein under the control of the SFFV promoter (13). The production, concentration and titration of FV were performed as described previously (13;17). Briefly, FV was produced in HEK-293T cells transfected with a 4-plasmid system using PEI<sub>max</sub> (Park Scientific Ltd., Northampton, UK) at a ratio of 3:1 PEI:DNA. Vector containing supernatant was concentrated by ultracentrifugation in an SW28 rotor at 19,000 rpm for 2 hours at 20°C. Pellets were re-suspended in PBS containing 5% vol/vol DMSO and aliquots were stored at -80°C. Vector titre was determined by qPCR on genomic DNA extracted from transduced HT1080 cells using primer/probes targeting the FV LTR and albumin as a reference gene as previously described (13). All MOIs are given in HT1080 transducing units per target cell.

### 3. Cell culture and transduction of human muscle derived stem cells with FV

Normal human skeletal muscle-derived CD133+ cells (18) and DMD myoblasts (with a mutation in dystrophin exon 52) were used for foamy virus vector transduction. Cells were maintained in M10 medium, consisting of Megacell DMEM media (Sigma) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher), 2mM Glutamine (Thermo Fisher) and 5ng/ml bFGF (Peprotech). Different amounts of vector were added to  $1 \times 10^5$  cells and the 6-well plates were spinoculated at 30°C at 1200g for 90 minutes. Cells were changed into fresh medium 6 hours after adding the vector. For FV-1-GFP, normal CD133+ cells were transduced at MOI 0, 1, 10, 20, 30 and 50; for coFLDys expressing FV, DMD myoblasts were transduced with vector at MOI 2, 4, 8 and 16. The transduced cells were then expanded in M10 medium for subsequent experiments.

#### 4. FACS analysis

For GFP-expressing FV transduced cells, the percentage of GFP+ cells and their mean fluorescent intensity (MFI) were measured 6 days after transduction, using a FACS calibur machine (BD). The data were analysed using flowjo software.

#### 5. Growth Curve assay

Cells transduced with FV-coFLDys were maintained in M10 medium for expansion. Cells were passaged once they reached around 70% confluency and cell number recorded. The growth curve were generated by plotting the number of population doublings the cells underwent (Y axis) over the time (days, X axis) in culture. The number of population doublings of the cells was calculated using the formula:  $\text{Ln}(\text{number of total cells at harvesting}/\text{number of cells at seeding})/\text{Ln}2$ .

#### 6. Immunofluorescent staining

Cultured cells were plated onto Matrigel (BD Bioscience, 0.1mg/ml) coated 8-well chamber slides at a density of  $5 \times 10^4$  cells/well in M10 medium. Cells were changed into Megacell DMEM containing 2% FBS to induce their myogenic differentiation. Cells fixed by 4% paraformaldehyde (PFA) before, or 5 days after the onset of differentiation, were immunostained using antibodies against dystrophin (Fisher Scientific, 1:1000) alone, for staining of non-differentiated cells, or together with an antibody against myosin (MF20, DSHB) for differentiated cells.

#### 7. Western blot

FV transduced cells were induced to undergo myogenic differentiation for 5 days before being lysed with Radio-Immunoprecipitation Assay (RIPA) buffer (Sigma), supplemented with protease inhibitor (Roche) on ice for 15 min. The cell lysate was collected and boiled for 5 min before being centrifuged at 14,000 x g for 10 minutes at 4°C. 30µl of each sample were loaded /well onto NuPAGE Novex 3-8% Tris-acetate gel, and run at a constant voltage of 150V for 1.5 hours, before being transferred to a PVDF membrane using trans-blot turbo transfer system (Bio-Rad). The membrane was blocked with Odyssey block solution (LI-COR Biosciences, Cambridge, UK) for one hour, before being incubated with primary antibodies against dystrophin (1:2000, Fisher Scientific) and tubulin 2.1 (1:1000, Santa Cruz) overnight at 4°C. After washing with PBS containing 0.1% Tween 20 (PBST) for 15 min x 3 times at room temperature, the membrane was incubated with biotinylated anti-rabbit secondary antibody (1:1000) for 2 hours, followed by IRDye 680RD Streptavidin and IRDye 800CW goat anti-mouse 2nd antibodies (1:15000, LI-COR Biosciences, Cambridge, UK) for 1 hour at RT. The image of the blotted membrane was acquired by Odyssey Clx infrared imaging system (LI-COR Biosciences, Cambridge, UK) using image studio software.

#### 8. Intramuscular transplantation

4-8 week-old male Rag2- $\gamma$  chain-/C5- mice (19;20) or male mdx nude mice (4;21) were used as recipients for cell transplantation. On the day of transplantation, mice were anesthetized with isoflurane in the afternoon (during the light cycle) and tibialis anterior (TA) muscles were cryodamaged with 3 freeze-thaw cycles using a cryo-probe pre-chilled in liquid nitrogen, to promote engraftment (21-23). Cryoinjury of mouse muscle mimics the degeneration that occurs in DMD patient muscles.

$5 \times 10^5$  cells in 5 µl medium were injected into each TA with a Hamilton syringe. Grafted muscles were dissected 4 weeks after transplantation and snap-frozen in isopentane chilled in liquid nitrogen. The n value is for the number of TA muscles. We use both hindlimb muscles, as they can be considered as independent units; cells transplanted intra-muscularly into one TA muscle have no effect on the

contralateral TA muscle. This is in accordance with the 3Rs guidelines (National Centre for the Replacement, Refinement and Reduction of Animals in Research).

9. Immunofluorescent staining on muscle sections

10  $\mu\text{m}$  transverse cryosections were cut throughout the muscle, air dried and blocked with mouse on mouse IgG blocking reagent for one hour and stained with the following combination of antibodies: 1) Antibodies against human spectrin (mouse IgG 2b, Vector labs, VP-S283, 1:100, Peterborough, UK), human lamin A/C (mouse IgG2b, Vector labs, VP-L550, 1:500, Peterborough, UK), and human dystrophin (Mandys 106, mouse IgG2a, 1:200, Millipore). The number of human lamin A/C+ nuclei, human spectrin+ fibres, human spectrin+ fibres containing at least one human lamin A/C+ nucleus (as a confirmation that the spectrin+ fibres were of donor origin) (24) were counted in representative transverse sections. The number of dystrophin+/hSpectrin+ fibres was also quantified to evaluate the percentage of dystrophin-expressing fibres of donor origin. The sections were scored by one observer. 2). Dystrophin (Mandys 106, mouse IgG2a) and  $\alpha$ -Sarcoglycan (mouse IgG1, 1:100, Leica biosystems). 3) Dystrophin (Mandys 106, mouse IgG2a, Millipore) and  $\gamma$ -sarcoglycan (rabbit polyclonal, 1:500, Santa Cruz); 4). Dystrophin (Mandys 106, mouse IgG2a, 1:100, Millipore) and nNOS (rabbit polyclonal, Santa Cruz); 5. Dystrophin (Mandys 106, mouse IgG2a) and utrophin (mouse IgG1, 1:200, Leica biosystems). The results were acquired using Axioscan slide scanner and the intensity of  $\alpha$ -sarcoglycan,  $\gamma$ -sarcoglycan, nNOS or utrophin on dystrophin+ or dystrophin- fibres was quantified using MetaMorph software. The correlation of the intensity of these proteins and the dystrophin intensity was analysed using GraphPad Prism 5.0 software.



## Results

### 1. FV transduced human muscle CD133+ cells contribute to muscle regeneration

We have previously shown that FV can transduce myoblasts *in vitro* (13) resulting in transgene expression in transduced myoblasts and the myotubes derived from these cells.

To determine whether FV-modified human muscle CD133+ cells can contribute to muscle regeneration *in vivo*, we transduced normal CD133+ cells (18) with foamy virus vector coding for GFP under the control of the phosphoglycerate kinase 1 (PGK) promoter at 1, 10, 20, 30 and 50 MOI. Six days post-transduction, cells expressed GFP in a dose-dependent manner (Figure 1a) at low MOI, but the percentage of GFP+ cells reached a plateau (around 76-80%) at MOI 10. Mean fluorescent intensity (MFI) of the transduced cells followed a similar trend. To avoid potential toxicity caused by the vector (25), we selected cells that were transduced with an MOI of 10 for subsequent experiments.

Transduced CD133+ cells were transplanted intramuscularly into cryodamaged tibialis anterior (TA) muscles (n=8) of immunodeficient C5- $\gamma$  chain-/Rag2- mice (19). Mice were perfused with 4% paraformaldehyde (PFA) (under terminal anaesthesia) 4 weeks after transplantation and transverse sections from the TA muscles were analysed by immunostaining of human lamin A/C and GFP. Human lamin A/C antibody recognises the nuclear protein lamin A/C specifically from human, not mouse cells and has been widely used as a human specific marker to distinguish donor cells from host tissue in human to mouse xenograft experiments (20;26;27). We found GFP+ muscle fibres within the transplanted muscles, and their donor cell origin was confirmed by the presence of human lamin A/C+ nuclei within the GFP+ fibres (Figure 1). These data demonstrate that FV can deliver a transgene into muscle CD133+ cells, without compromising their ability to contribute to muscle regeneration after *in vivo* transplantation.

## 2. Transduction of FV encoding codon-optimized full-length dystrophin into DMD myoblasts

We then investigated delivery of FL-dys into myoblasts using FV vector. We previously reported (13) that FV encoding coFLDys under the control of SFFV-promoter transduced DMD myoblasts, resulting in FL-dys expression in differentiated myotubes derived from these myoblasts. Using the same FV vector, we transduced  $1 \times 10^5$  DMD myoblasts with concentrated FV-coFLDys at MOI of 2, 4, 8 and 16, and determined the proliferation rate of transduced cells, by plotting the population doublings of the cells over the days in culture. The vector elicited a dose-dependent toxicity when high MOI ( $\geq 4$ ) were used, as indicated by the cessation of proliferation of transduced cells (Fig 2a). Only cells transduced with MOI 2 FV-coFLDys survived and proliferated, but with a compromised proliferation rate in comparison to the non-transduced cells. Nevertheless, these transduced cells could still proliferate to generate sufficient cells for the *in vivo* transplantation study.

We then examined the transgene expression of the MOI 2 FV-coFLDys transduced cells. We found that  $42.19 \pm 6.91\%$  of transduced myoblasts were dystrophin+ (Figure 2b); after inducing these cells to differentiate into myotubes,  $55.22 \pm 8.73\%$  of differentiated myotubes expressed dystrophin.

To confirm that the dystrophin was of the expected molecular weight, we performed western blotting using myotubes differentiated from either non-transduced or transduced cells; myotubes differentiated from normal skeletal muscle-derived CD133+ cells were included as a positive control. There was a clear 427kD dystrophin band in samples from both positive controls and transduced cells, in comparison to the absence of such a band in non-transduced cells (Figure 2c).

### 3. Transduced DMD-myoblasts contribute to muscle regeneration and express full-length dystrophin in all donor-derived muscle fibres

Transduced cells were transplanted into cryodamaged TA muscles of mdx nude mice (4;21) to determine their contribution to muscle regeneration and restoration of dystrophin *in vivo*.

Twenty-eight days after transplantation, the muscles were removed and cryosections stained for antibodies against human lamin A/C (to determine the number of cells of donor origin within host muscle), human spectrin (to determine the number of muscle fibres of donor origin; the combination of both antibodies confirmed the donor origin of the muscle fibres) (24), and human dystrophin (Mandys 106) (to determine the number of muscle fibres of donor origin which express dystrophin). The ratio of fibres containing dystrophin to those containing human spectrin and a human lamin A/C+ nucleus indicates the efficiency of dystrophin restoration in donor-derived muscle fibres.

All transplanted muscles contained donor-derived muscle fibres (Figure 3). There were significantly more myofibres expressing human dystrophin ( $131.3 \pm 4.129$ , mean  $\pm$  SEM, n=8) than human spectrin and human lamin A/C ( $116 \pm 11.71$ , mean  $\pm$  SEM, n=8), suggesting that dystrophin had been restored in all of the donor-derived muscle fibres.

### 4. Transplanted Dystrophin-expressing fibres recruit $\alpha$ -sarcoglycan and $\gamma$ -sarcoglycan to the sarcolemma

When dystrophin is not present within a myofibre, other members of the dystrophin-associated protein complex (DAPC) are also absent or severely reduced (28). To determine if the restored dystrophin was functional, we investigated whether it recruited members of the DAPC at the sarcolemma of donor-derived myofibres (4;29).

We carried out double immunostaining with antibodies to human dystrophin (Mandys 106) and members of dystrophin glycoprotein complex ( $\alpha$ -sarcoglycan or  $\gamma$ -sarcoglycan), to examine their co-localization on muscle fibres.

Human dystrophin+ muscle fibres expressed higher levels of  $\alpha$ -sarcoglycan (Figure 4 a, b and c) or  $\gamma$ -sarcoglycan (Figure 4 d, e and f), than did human dystrophin- muscle fibres in the same muscle section. Within the 8 transplanted muscles, the intensity of the  $\alpha$ -sarcoglycan or  $\gamma$ -sarcoglycan in human dystrophin+ fibres is significantly higher than in dystrophin- fibres (Figure 4g, i and supplementary Figure 1 and 2), as determined by paired t-test ( $p=0.0006$  for  $\alpha$ -sarcoglycan and  $p<0.0001$  for  $\gamma$ -sarcoglycan). Linear regression analysis of the intensity of dystrophin and  $\alpha$ -sarcoglycan demonstrated significant positive correlation between the two proteins at the sarcolemma of all the donor-derived muscle fibres (Figure 4h shows data from one representative transplanted muscle; and supplementary Figure S1). Similarly, linear regression analysis of the intensity of dystrophin and  $\gamma$ -sarcoglycan also showed significant positive correlation within all transplanted muscles (Figure 4j, data from one representative muscle; supplementary Figure S2).

#### 5. Restored dystrophin recruits nNOS to the sarcolemma of the donor fibres

nNOS is an important signalling molecule in skeletal muscle whose sarcolemma location relies on its binding with dystrophin at R16-R17 of the spectrin-like repeats of dystrophin (30;31). To determine whether the restored full length dystrophin was capable of recruiting nNOS at the sarcolemma, double immunostaining with Mandys 106 and an antibody to nNOS was carried out on transplanted muscle sections. In dystrophin- muscle fibres, there was either no, or very low levels, of nNOS expression at the sarcolemma, while there was clear expression of nNOS on dystrophin+ muscle fibres (Figure 5a-c). The intensity of nNOS at the sarcolemma of the dystrophin+ fibres was significantly higher than dystrophin- muscle fibres, as shown by the paired t-test of the 8 transplanted muscles (Figure 5d, supplementary Figure S3). Linear regression analysis of the intensity of nNOS and dystrophin showed significant positive correlation of the expression of the two proteins at the sarcolemma of the dystrophin+ fibres (Figure 5e, supplementary Figure S3).

## 6. Donor derived dystrophin-expressing muscle fibres express lower levels of utrophin than host muscle fibres.

Utrophin is an autosomal homologue of dystrophin which is upregulated in dystrophin-deficient mouse models and in DMD patients, partially compensating for the lack of dystrophin (32;33). Double immunostaining of dystrophin and utrophin on sections of transplanted muscles showed that the sarcolemmal utrophin expression was significantly lower on dystrophin+ than dystrophin- fibres, compared by paired t-test of the 8 transplanted muscles (Figure 6). Interestingly, unlike the DAPC and nNOS, there was no correlation between utrophin and dystrophin intensity at the sarcolemma of the same muscle fibres (Figure 6, supplementary figure S4).

## Discussion

Duchenne Muscular Dystrophy is a genetic disorder characterised by muscle wasting and progressive muscle weakness, caused by loss of dystrophin. There is no cure for DMD, although several therapeutic approaches are in pre-clinical, or clinical, development (34-36).

Viral vectors have been developed to restore dystrophin expression, the most promising being AAV (37;38). In animal models of DMD, AAV vectors coding for micro-dystrophin transduced the majority of muscle fibres following systemic delivery, leading to widespread dystrophin restoration (39-41). However, as AAV has a negligible integration rate *in vivo*, and immunity to the virus capsid occurs (40), it can only be delivered once and dystrophin expression may decline with time and as a consequence of cell turnover. Moreover, AAV has a small packaging capacity, so it can only restore small, partially functional dystrophin isoforms. After treatment, the muscle of DMD patient are expected to be partially protected from further deterioration, in a similar way to the relative protection conferred in patients with Becker Muscular Dystrophy (BMD) by the internally deleted proteins these patients typically produce, rather than a normal phenotype. To fully restore dystrophin function, it is necessary to deliver full-length, rather than mini, dystrophin; however this is challenging to package into viral

vectors. We have already shown that either FV (13) or LV (12) can package full-length dystrophin and transduce DMD myoblasts *in vitro*, suggesting that both vectors would be suitable to restore fully-functional dystrophin. However, the efficacy of these viral vectors needs to be tested *in vivo*.

Direct delivery of FV or LV via i.v injection *in vivo* is limited by the relatively low titre that can be achieved for these vectors. The alternative is to use them for cell-mediated gene therapy. This would require autologous stem cells, which is an advantage in avoiding or reducing immunological rejection of the transplanted cells.

Foamy virus vector has been used for cell-mediated gene therapy in animal models. In canine model of pyruvate kinase deficiency, following transplantation with hematopoietic stem cells (HSCs) transduced *ex vivo* using a tri-cistronic FV vector that expressed EGFP, R-type pyruvate kinase, and MGMP140K, the myeloid long-term repopulating cells increased from approximately 3.5% to 33%, resulting in a functional cure (11). A longer term follow up study in canine models of leukocyte adhesion deficiency (CLAD) (42) which were treated with autologous, CD34(+) HSCs transduced by a FV vector expressing canine CD18, showed disease correction/amelioration of disease in CLAD without significant adverse events, supporting the use of a FV vector to treat children with leukocyte adhesion deficiency type 1 (LAD-1) in a human gene therapy clinical trial. But this strategy has not been tested before on models of muscle diseases.

Firstly we showed that FV can transduce CD133+ cells and that these cells give rise to transgene (GFP)-expressing myofibres after their intra-muscular transplantation in an immunodeficient mouse model (Figure 1). These data suggested the FV transduced autologous cells could be potentially used to treat diseases such as muscular dystrophy.

As a tracking marker, GFP is frequently used in basic research or pre-clinical studies to generate proof of principle data. However, GFP is toxic and immunogenic *in vivo* (16), which is not suitable for clinical application. Thus a simple and efficient delivery system without the need of FACS sorting after transduction is necessary if contemplating future clinical applications. To meet this requirement, we chose to use a FV-coFLDys vector

that did not contain a GFP selection cassette, to transduce DMD myoblasts at early mean population doublings. Transduced cells were then transplanted into *mdx* nude mice without either FACS sorting, or extensive expansion *in vitro*, that reduces muscle stem cell engraftment efficiency (18;43;44). Our results provide the first evidence that the coFLDys ORF could be delivered to DMD myoblasts via FV, and the transduction efficiency is high enough to ensure the downstream *in vivo* restoration of FL-dys protein by donor cells, without the need of *in vitro* selection.

In transverse sections of grafted muscles, there were more fibres expressing human dystrophin than fibres expressing human spectrin and containing a human lamin A/C+ nucleus, evidence of highly effective dystrophin restoration. This is likely to be because the full-length dystrophin sequence is codon-optimized, which results in higher protein expression than native cDNA (13-15). Transduced cells containing the integrated virus may fuse with either non-transduced cells (*in vitro*); or dystrophin-deficient host muscle fibres (*in vivo*), resulting in mosaic myotubes or myofibres. Such mosaic fibres might contain myonuclei derived from human FV-transduced cells that would produce dystrophin, or myonuclei either of mouse origin, and/or derived from non-transduced human cells, that would not produce dystrophin. Myonuclei derived from codon optimized full-length dystrophin transduced cells seem to produce sufficient dystrophin to spread a reasonable distance (further than human spectrin) along the fibre.

We examined the muscles at 4 weeks after transplantation, giving sufficient time for the muscle to regenerate post-injury. We did not examine muscles at later timepoints, which, although of clinical relevance, would be challenging to do, as immunodeficient mice have a shorter lifespan than non-immunodeficient mice (45) and xenografts may undergo some degree of immunological rejection even within immunodeficient mouse hosts.

Utrophin is an autosomally-encoded homologue of dystrophin (46) which in normal muscle, is located at the neuromuscular junction and is absent at sarcolemma of the muscle fibres. It is upregulated at the sarcolemma in dystrophin-negative myofibres to partially compensate for the lack of dystrophin (47-50). We examined the expression intensity of utrophin in treated muscle, focusing on the sarcolemma of the muscle

fibres. When full-length dystrophin was restored, the expression of utrophin decreased at the myofibre sarcolemma. As our transplanted muscles will have regenerated as a response to cryoinjury, we expect that the utrophin distribution at the neuromuscular junction of myofibres would be dysregulated (51). Our findings suggest that the coFLDys outcompetes utrophin and suppresses its expression. However, unlike the DAPC proteins in serial sections, there was no correlation of utrophin and dystrophin intensity on the same muscle fibres (Figure 6, S4). This is understandable, as the majority of the dystrophin+ fibres do not have utrophin at the sarcolemma.

We did not perform any physiological studies on our transplanted mouse muscles. It has been shown that 20% of myofibres in a mouse TA muscle need to express dystrophin to give a significant protection against contraction-induced injury (52) and that 20-30% of endogenous dystrophin levels are required to reduce the mdx muscle pathology and to avoid muscular dystrophy in humans (53-55). In our study, we obtained a mean of 130 fibres expressing dystrophin in a representative transverse section (Figure 3). A mouse mdx tibialis anterior muscle contains approximately 2,200 myofibres (56-58).

Therefore, we estimate that approximately 6% of the myofibres contain human dystrophin. Dystrophin expression derived from cells that have contributed to degenerating mouse myofibres is likely to be segmental (43;59), so dystrophin would not be present along the whole fibre and thus would be unlikely to be of physiological benefit to the muscle (60-62). Reaching this level of engraftment remains a major challenge in the muscle stem cell therapy field, but this might be achievable when human cells are transplanted into patients, particularly if they contribute to the satellite cell pool.

One big concern in applying viral vectors for gene therapy is possible mutagenesis or oncogenesis caused by the random integration of the vectors. There is evidence that foamy virus would be sufficiently low-risk for clinical application. While the wild type foamy virus has not been associated with disease in any animal, large scale integration site analyses on FV-transduced human fibroblasts, CD34+ cells (10) and 293 cells (9) suggest that FV have a favourable integration profile compared to other retroviral vectors. In contrast to lentivirus vectors, FV vectors have no preference for integration



within genes. Similarly, FV vectors have only a weak preference for integration near CpG islands and transcription start sites when compared to the strong bias exhibited by MLV vectors (63). Moreover, FVs have been found to contain a strong chromatin insulator within their LTR that significantly limits genotoxicity (64). Consistent with this, an analysis in human iPSC cells (65) suggested that integrated FV proviruses do not impact the expression of chromosomal genes in pluripotent human stem cells or their differentiated derivatives even when integrating near or within genes. Although FV vectors appear to be the safest integrating vector available, integration site analysis in human muscle progenitor cells would be appropriate for clinical use.

In summary, our work demonstrated for the first time the efficacy of a novel potential therapeutic approach for DMD treatment, combining the advantages of autologous cell therapy and full-length dystrophin restoration *in-vivo*. The use of autologous rather than donor-derived stem cells will reduce the risk of immunological rejection and the need for life-long immunosuppression. These stem cells contain a dystrophin construct that will express dystrophin once they have formed muscle fibres following their local delivery to patient muscles, hence eliminating the underlying cause of muscle fibre loss. Also, in contrast to exon skipping, or gene editing, this cell-mediated FL-dys therapy is applicable to all DMD patients, regardless of their mutation.

Given that systemic delivery of skeletal muscle stem cells remains challenging (66), autologous skeletal muscle stem cells transduced with FLdys could be injected intramuscularly to treat small muscles of a patient. For example, the direct injection of stem cells into the thenar muscles should reduce the progression of the disease in hand muscles, leading to an improvement of function in the hand which would make a significant difference to non-ambulant DMD patients for maintaining independent daily life activities. For this kind of local injection, both obtaining sufficient cells from a muscle biopsy to treat such a small muscle, and sufficient FL-Dys vector to transduce the cells, would be feasible. There are muscles in DMD patients, e.g. the extensor digitorum brevis muscle in the foot, that are relatively well-preserved in DMD (67), so this muscle would be a good candidate from which to prepare muscle precursor cells for therapeutic application (68). With this strategy, only a single application of transduced stem cells is required for a long-lasting effect. Unlike AAV gene therapy that

requires viable muscle fibres (and would therefore be unsuitable for older DMD patients, who would have already lost a significant proportion of their muscle mass), stem cell therapy should replenish the stem cell pool, repair degenerating muscle fibres and make new muscle fibres. In the future, local stem cell therapy (delivering FL-Dys) combined with systemic AAV therapy (delivering mini-dystrophin) may be explored, to take advantage of the two separate approaches.

### **Acknowledgements**

The MRC Centre for Neuromuscular Diseases Biobank, supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London and NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London, is gratefully acknowledged.

Funding: This work was funded by the MRC (grant number G0900872). NPS was supported by Wellcome Trust PhD studentship (093610/Z/10/A) and Jefferiss Research Trust Fellowship. JEM was supported by Great Ormond Street Hospital Children's Charity. The support of MDUK and the MRC Centre for Neuromuscular Diseases is also gratefully acknowledged. NPS and MOM are grateful to the NIHR BRC at Imperial NHS Trust for its support. Part of this research – using DMD patients' cells- was supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

### **Author Disclosure Statement**

No competing financial interests exist.

## Reference List

- (1) Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. *Ann Neurol* 2012 Mar;71(3):304-13.
- (2) Sacco A, Doyonnas R, Kraft P, Vitorovic S, Blau HM. Self-renewal and expansion of single transplanted muscle stem cells. *Nature* 2008 Nov 27;456(7221):502-6.
- (3) Collins CA, Olsen I, Zammit PS, Heslop L, Petrie A, Partridge TA, et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. *Cell* 2005 Jul 29;122(2):289-301.
- (4) Meng J, Counsell JR, Reza M, Laval SH, Danos O, Thrasher A, et al. Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy. *Sci Rep* 2016 Jan 27;6:19750.
- (5) Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, et al. A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. *Cell Stem Cell* 2016 Apr 7;18(4):533-40.
- (6) Amoasii L, Long C, Li H, Mireault AA, Shelton JM, Sanchez-Ortiz E, et al. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. *Sci Transl Med* 2017 Nov 29;9(418).
- (7) Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, et al. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. *Nat Commun* 2017 Feb 14;8:14454.
- (8) Trobridge GD. Foamy virus vectors for gene transfer. *Expert Opin Biol Ther* 2009 Nov;9(11):1427-36.

- (9) Nowrouzi A, Dittrich M, Klanke C, Heinkelein M, Rammling M, Dandekar T, et al. Genome-wide mapping of foamy virus vector integrations into a human cell line. *J Gen Virol* 2006 May;87(Pt 5):1339-47.
- (10) Trobridge GD, Miller DG, Jacobs MA, Allen JM, Kiem HP, Kaul R, et al. Foamy virus vector integration sites in normal human cells. *Proc Natl Acad Sci U S A* 2006 Jan 31;103(5):1498-503.
- (11) Trobridge GD, Beard BC, Wu RA, Ironside C, Malik P, Kiem HP. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency. *PLoS One* 2012;7(9):e45173.
- (12) Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, et al. Lentiviral vectors can be used for full-length dystrophin gene therapy. *Sci Rep* 2017 Mar 6;7(1):79.
- (13) Sweeney NP, Meng J, Patterson H, Morgan JE, McClure M. Delivery of large transgene cassettes by foamy virus vector. *Sci Rep* 2017 Aug 14;7(1):8085.
- (14) Foster H, Sharp PS, Athanasopoulos T, Trollet C, Graham IR, Foster K, et al. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. *Mol Ther* 2008 Nov;16(11):1825-32.
- (15) Inouye S, Sahara-Miura Y, Sato J, Suzuki T. Codon optimization of genes for efficient protein expression in mammalian cells by selection of only preferred human codons. *Protein Expr Purif* 2015 May;109:47-54.
- (16) Ansari AM, Ahmed AK, Matsangos AE, Lay F, Born LJ, Marti G, et al. Cellular GFP Toxicity and Immunogenicity: Potential Confounders in in Vivo Cell Tracking Experiments. *Stem Cell Rev* 2016 Oct;12(5):553-9.
- (17) Sweeney NP, Regan C, Liu J, Galleu A, Dazzi F, Lindemann D, et al. Rapid and Efficient Stable Gene Transfer to Mesenchymal Stromal Cells Using a Modified Foamy Virus Vector. *Mol Ther* 2016 Aug;24(7):1227-36.

- (18) Meng J, Chun S, Asfahani R, Lochmuller H, Muntoni F, Morgan J. Human skeletal muscle-derived CD133(+) cells form functional satellite cells after intramuscular transplantation in immunodeficient host mice. *Mol Ther* 2014 May;22(5):1008-17.
- (19) Ehrhardt J, Brimah K, Adkin C, Partridge T, Morgan J. Human muscle precursor cells give rise to functional satellite cells in vivo. *Neuromuscul Disord* 2007 Aug;17(8):631-8.
- (20) Silva-Barbosa SD, Butler-Browne GS, Di Santo JP, Mouly V. Comparative analysis of genetically engineered immunodeficient mouse strains as recipients for human myoblast transplantation. *Cell Transplant* 2005;14(7):457-67.
- (21) Meng J, Bencze M, Asfahani R, Muntoni F, Morgan JE. The effect of the muscle environment on the regenerative capacity of human skeletal muscle stem cells. *Skelet Muscle* 2015;5:11.
- (22) Irintchev A, Zweyer M, Wernig A. Impaired functional and structural recovery after muscle injury in dystrophic mdx mice. *Neuromuscul Disord* 1997 Mar;7(2):117-25.
- (23) Mueller AL, Bloch RJ. Skeletal muscle cell transplantation: models and methods. *J Muscle Res Cell Motil* 2019 Aug 7.
- (24) Rozkalne A, Adkin C, Meng J, Lapan A, Morgan JE, Gussoni E. Mouse regenerating myofibers detected as false-positive donor myofibers with anti-human spectrin. *Hum Gene Ther* 2014 Jan;25(1):73-81.
- (25) Nasimuzzaman M, Lynn D, Ernst R, Beuerlein M, Smith RH, Shrestha A, et al. Production and purification of high-titer foamy virus vector for the treatment of leukocyte adhesion deficiency. *Mol Ther Methods Clin Dev* 2016;3:16004.
- (26) Lorant J, Saury C, Schleder C, Robriquet F, Lieubeau B, Negroni E, et al. Skeletal Muscle Regenerative Potential of Human MuStem Cells following Transplantation into Injured Mice Muscle. *Mol Ther* 2018 Feb 7;26(2):618-33.

- (27) Xu X, Wilschut KJ, Kouklis G, Tian H, Hesse R, Garland C, et al. Human Satellite Cell Transplantation and Regeneration from Diverse Skeletal Muscles. *Stem Cell Reports* 2015 Sep 8;5(3):419-34.
- (28) Ohlendieck K, Matsumura K, Ionasescu VV, Towbin JA, Bosch EP, Weinstein SL, et al. Duchenne muscular dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. *Neurology* 1993 Apr;43(4):795-800.
- (29) Cirak S, Feng L, Anthony K, Arechavala-Gomez V, Torelli S, Sewry C, et al. Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. *Mol Ther* 2012 Feb;20(2):462-7.
- (30) Molza AE, Mangat K, Le RE, Hubert JF, Menhart N, Delalande O. Structural Basis of Neuronal Nitric-oxide Synthase Interaction with Dystrophin Repeats 16 and 17. *J Biol Chem* 2015 Dec 4;290(49):29531-41.
- (31) Lai Y, Zhao J, Yue Y, Duan D. alpha2 and alpha3 helices of dystrophin R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for neuronal NOS binding. *Proc Natl Acad Sci U S A* 2013 Jan 8;110(2):525-30.
- (32) Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS, et al. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. *Proc Natl Acad Sci U S A* 2011 Jan 11;108(2):762-7.
- (33) Banks GB, Combs AC, Odom GL, Bloch RJ, Chamberlain JS. Muscle structure influences utrophin expression in mdx mice. *PLoS Genet* 2014 Jun;10(6):e1004431.
- (34) Messina S, Vita GL. Clinical management of Duchenne muscular dystrophy: the state of the art. *Neurol Sci* 2018 Nov;39(11):1837-45.
- (35) Chamberlain JR, Chamberlain JS. Progress toward Gene Therapy for Duchenne Muscular Dystrophy. *Mol Ther* 2017 May 3;25(5):1125-31.

- (36) Reinig AM, Mirzaei S, Berlau DJ. Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies. *Pharmacotherapy* 2017 Apr;37(4):492-9.
- (37) Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. *Mol Ther* 2018 Oct 3;26(10):2337-56.
- (38) Kawecka K, Theodoulides M, Hasoglu Y, Jarmin S, Kymalainen H, Le-Heron A, et al. Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD). *Curr Gene Ther* 2015;15(4):395-415.
- (39) Kodippili K, Hakim CH, Pan X, Yang HT, Yue Y, Zhang Y, et al. Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model. *Hum Gene Ther* 2018 Mar;29(3):299-311.
- (40) Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. *Mol Ther* 2007 Jun;15(6):1160-6.
- (41) Le GC, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. *Nat Commun* 2017 Jul 25;8:16105.
- (42) Bauer TR, Jr., Tuschong LM, Calvo KR, Shive HR, Burkholder TH, Karlsson EK, et al. Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency. *Mol Ther* 2013 May;21(5):964-72.
- (43) Brimah K, Ehrhardt J, Mouly V, Butler-Browne GS, Partridge TA, Morgan JE. Human muscle precursor cell regeneration in the mouse host is enhanced by growth factors. *Hum Gene Ther* 2004 Nov;15(11):1109-24.


- (44) Cooper RN, Thiesson D, Furling D, Di Santo JP, Butler-Browne GS, Mouly V. Extended amplification in vitro and replicative senescence: key factors implicated in the success of human myoblast transplantation. *Hum Gene Ther* 2003 Aug 10;14(12):1169-79.
- (45) Boldrin L, Zammit PS, Muntoni F, Morgan JE. Mature adult dystrophic mouse muscle environment does not impede efficient engrafted satellite cell regeneration and self-renewal. *Stem Cells* 2009 Oct;27(10):2478-87.
- (46) Blake DJ, Tinsley JM, Davies KE. Utrophin: a structural and functional comparison to dystrophin. *Brain Pathol* 1996 Jan;6(1):37-47.
- (47) Guiraud S, Edwards B, Babbs A, Squire SE, Berg A, Moir L, et al. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. *Hum Mol Genet* 2019 Jul 1;28(13):2189-200.
- (48) Banks GB, Combs AC, Odom GL, Bloch RJ, Chamberlain JS. Muscle structure influences utrophin expression in mdx mice. *PLoS Genet* 2014 Jun;10(6):e1004431.
- (49) Pons F, Robert A, Marini JF, Leger JJ. Does utrophin expression in muscles of mdx mice during postnatal development functionally compensate for dystrophin deficiency? *J Neurol Sci* 1994 Apr;122(2):162-70.
- (50) Weir AP, Morgan JE, Davies KE. A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. *Neuromuscul Disord* 2004 Jan;14(1):19-23.
- (51) Ferretti R, Neto HS, Marques MJ. Expression of utrophin at dystrophin-deficient neuromuscular synapses of mdx mice: a study of protected and affected muscles. *Anat Rec (Hoboken)* 2011 Feb;294(2):283-6.
- (52) Sharp PS, Jee H, Wells DJ. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. *Mol Ther* 2011 Jan;19(1):165-71.




- (53) Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L, et al. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. *Neuromuscul Disord* 2007 Dec;17(11-12):913-8.
- (54) Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. *Hum Mol Genet* 1995 Aug;4(8):1251-8.
- (55) Wells DJ, Wells KE, Asante EA, Turner G, Sunada Y, Campbell KP, et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. *Hum Mol Genet* 1995 Aug;4(8):1245-50.
- (56) Vitiello L, Bassi N, Campagnolo P, Zaccariotto E, Occhi G, Malerba A, et al. In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle. *Neuromuscul Disord* 2008 Aug;18(8):597-605.
- (57) Williams JH, Schray RC, Sirsi SR, Lutz GJ. Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice. *BMC Biotechnol* 2008 Apr 2;8:35.
- (58) Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, et al. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. *Hum Mol Genet* 2008 Dec 15;17(24):3909-18.
- (59) Blaveri K, Heslop L, Yu DS, Rosenblatt JD, Gross JG, Partridge TA, et al. Patterns of repair of dystrophic mouse muscle: studies on isolated fibers. *Dev Dyn* 1999 Nov;216(3):244-56.
- (60) Aartsma-Rus A, Morgan J, Lonkar P, Neubert H, Owens J, Binks M, et al. Report of a TREAT-NMD/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology. *J Neuromuscul Dis* 2019;6(1):147-59.

- (61) Godfrey C, Muses S, McClorey G, Wells KE, Coursindel T, Terry RL, et al. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. *Hum Mol Genet* 2015 Aug 1;24(15):4225-37.
- (62) Wells DJ. What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy? *J Muscle Res Cell Motil* 2019 Jun;40(2):141-50.
- (63) Nasimuzzaman M, Kim YS, Wang YD, Persons DA. High-titer foamy virus vector transduction and integration sites of human CD34(+) cell-derived SCID-repopulating cells. *Mol Ther Methods Clin Dev* 2014;1:14020.
- (64) Goodman MA, Arumugam P, Pillis DM, Loberg A, Nasimuzzaman M, Lynn D, et al. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential. *J Virol* 2018 Jan 1;92(1).
- (65) Deyle DR, Khan IF, Ren G, Russell DW. Lack of genotoxicity due to foamy virus vector integration in human iPSCs. *Gene Ther* 2013 Aug;20(8):868-73.
- (66) Cossu G, Previtali SC, Napolitano S, Cicalese MP, Tedesco FS, Nicastro F, et al. Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. *EMBO Mol Med* 2015 Dec;7(12):1513-28.
- (67) Kinali M, Arechavala-Gomez V, Cirak S, Glover A, Guglieri M, Feng L, et al. Muscle histology vs MRI in Duchenne muscular dystrophy. *Neurology* 2011 Jan 25;76(4):346-53.
- (68) Meng J, Adkin CF, Xu SW, Muntoni F, Morgan JE. Contribution of human muscle-derived cells to skeletal muscle regeneration in dystrophic host mice. *PLoS One* 2011 Mar 9;6(3):e17454.


## Figure legends




**Figure 1. Human skeletal muscle CD133+ cells retain their *in vivo* myogenic capacity post-transduction with FV.** The percentage of GFP+ cells (a) and the mean fluorescence intensity (b) of cells transduced with different MOI of foamy virus coding for GFP, 6 days after transduction. (c) the contribution of transduced cells (MOI 10) to muscle regeneration after their intramuscular transplantation into immunodeficient mice. Donor-derived nuclei expressed human lamin AC+ (red), and donor muscle fibres were identified by their GFP expression. Scale bar=25 $\mu$ m.



**Figure 2. *In vitro* transduction of human DMD myoblasts with FV-coFLDys.** (a) *in vitro* proliferation curve of cells transduced with different amounts of FVs, for 30 days after their transduction. (b) the expression of dystrophin in cells with FV of MOI 2. (c) Western blot indicating the correct molecular weight of the transgene in differentiated myotubes derived from the transduced cells. (d-f) immunostaining of myosin heavy chain (d, green), dystrophin (e, red) and merged images (f). Nuclei were counterstained with DAPI. Scale bar=25 $\mu$ m.




**Figure 3. FV-coFLDys-transduced DMD myoblasts contribute to muscle regeneration after intramuscular transplantation into immunodeficient mdx nude mice.** (a-c) immunostaining of human lamin AC/human spectrin (a, both red); human dystrophin (green, b), (c) merged image of a and b. (d and e) quantification of the number of human spectrin+ fibres which contained at least one human lamin A/C+ nucleus (S+L); and dystrophin+ fibres in each transplanted muscle.




**Figure 4. Restored full-length dystrophin recruits members of the DAPC at the sarcolemma of donor-derived myofibres *in vivo*.** (a-c) immunostaining of dystrophin (green, a) and  $\alpha$ -sarcoglycan (red, b) on donor fibres. (c) merged image of a and b. (d-f) immunostaining of dystrophin (green, d) and  $\gamma$ -sarcoglycan (red, e). (f) merged image of d and e. (g) intensity of  $\alpha$ -sarcoglycan on dystrophin+ fibres and dystrophin- fibres within the transplanted muscle. Data were compared using paired t-test. (h) linear regression of the intensity of  $\alpha$ -sarcoglycan and dystrophin in a transverse section of a representative muscle. (i) intensity of  $\gamma$ -sarcoglycan on dystrophin+ fibres and dystrophin- fibres within transplanted muscles; data were compared using paired t-test. (j) linear regression of the intensity of  $\gamma$ -sarcoglycan and dystrophin in a transverse section of a representative muscle. Scale bar=50 $\mu$ m.





**Figure 5. Upregulation of nNOS on dystrophin+ donor-derived myofibres within transplanted muscles.** (a-c) immunostaining of dystrophin (green, a) and nNOS (red, b). (c) merged image of a and b. Scale bar=50μm. (d) quantification of the intensity of nNOS on dystrophin+ and dystrophin- fibres; data were compared using paired t-test. (e) linear regression analysis of the intensity of nNOS and dystrophin in a transverse cryosection of a representative muscle showed positive correlation of the two proteins in donor-derived muscle fibres.



**Figure 6. Restoration of dystrophin decreases the utrophin expression on donor-derived fibres.** (a-f) immunostaining of dystrophin (green, a and d) and utrophin (red, b and e) in transplanted muscles. (c, f) merged image of a and b, or d and e, respectively. (d-f) enlarged images of the square in a-c. Scale bar=50 $\mu$ m. (g) paired t-test of the intensity of utrophin in dystrophin+ and dystrophin- fibres. (h) linear regression analysis of the intensity of the utrophin and dystrophin in dystrophin+ donor fibres from one of the representative muscles suggested no correlation of the expression of the two proteins.



**Figure S1. Quantification of the intensity of  $\alpha$ -sarcoglycan in dystrophin+ and dystrophin-fibres in transverse sections of each transplanted muscle** (a). Linear regression analysis of the intensity of the  $\alpha$ -sarcoglycan and dystrophin shows a positive correlation of the two proteins on donor-derived muscle fibres in all the transplanted muscles (b).

**Figure S2. Quantification of the intensity of  $\gamma$ -sarcoglycan in dystrophin+ and dystrophin-fibres in transverse sections of each transplanted muscle** (a). Linear regression analysis of the intensity of the  $\gamma$ -sarcoglycan and dystrophin shows a positive correlation of the two proteins on donor-derived muscle fibres in all the transplanted muscles (b).

**Figure S3. Quantification of the intensity of nNOS in dystrophin+ and dystrophin- fibres in transverse sections of each transplanted muscle** (a). Linear regression analysis of the intensity of the nNOS and dystrophin shows a positive correlation of the two proteins on donor-derived muscle fibres in all the transplanted muscles (b).

**Figure S4: Quantification of the intensity of utrophin in dystrophin+ and dystrophin-fibres in transverse sections of each transplanted muscle** (a). Linear regression analysis of the intensity of the utrophin and dystrophin suggested no correlation of the two proteins on donor-derived muscle fibres in all the transplanted muscles (b).